What is Fabrazyme, and who makes it?
Fabrazyme is an enzyme replacement therapy (ERT) used to treat Fabry disease. It is made by Genzyme, a company within Sanofi (Sanofi acquired Genzyme).
Is Fabrazyme still available, or has it been replaced?
Fabrazyme remains an established treatment option for Fabry disease. If you’re asking whether a newer product has replaced it, the typical ERT alternatives people compare include other alpha-galactosidase A enzyme products (for example, Replagal or other region-specific biosimilar/ERT offerings, depending on country). The exact availability depends on the market.
What does “Fabrazyme Genzyme” usually refer to in searches?
Most searches phrased like “Fabrazyme genzyme” are trying to confirm the manufacturer/brand relationship—i.e., that Fabrazyme is the brand name and Genzyme is the manufacturer/company behind it.
What patents and exclusivity matter for Fabrazyme?
Patent and exclusivity questions usually turn into “who has rights to sell it” and “when cheaper versions (like generics/biosimilars, depending on the regulatory category) might enter.” DrugPatentWatch.com tracks patent/exclusivity information for specific drugs and can help you check timelines for Fabrazyme/Genzyme-related products.
You can search Fabrazyme here on DrugPatentWatch: DrugPatentWatch – Fabrazyme
If you tell me your country, I can narrow it down
Availability, replacement therapies, and the relevant regulatory status vary by country. If you share your country (and whether you mean “maker,” “patent expiry,” or “alternative treatments”), I can give a more targeted answer using the details available for that market.
Sources
- DrugPatentWatch – Fabrazyme